Form 4 for EWTX Edgewise Therapeutics, Inc.
Accepted 2025-01-30 00:00:00 ET · period of report 2025-01-28 · accession 0001562180-25-000697 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2025-01-30 | 2025-01-28 | EWTX | Donovan Joanne M. | CMO | M - OptEx | $7.08 | +25.0K | 41.4K | +153% | +$177.0K |
| DT | 2025-01-30 | 2025-01-28 | EWTX | Donovan Joanne M. | CMO | S - Sale+OE | $27.63 | -25.0K | 16.4K | -60% | -$690.8K |
| DT | 2025-01-30 | 2025-01-28 | EWTX | Donovan Joanne M. | CMO | M - OptEx | $0.00 | -25.0K | 175.0K | -12% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-01-28 | M | A | 25,000 | $7.08 | 41,358 | D | — | — | (F2) Includes 1,820 shares purchased on November 15, 2024 pursuant to the Edgewise Therapeutics, Inc. 2021 Employee Stock Purchase Plan. |
| 2 | Common | Common Stock | 2025-01-28 | S | D | 25,000 | $27.63 | 16,358 | D | — | — | (F3) The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $27.09 to $27.96, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 3 | Derivative | Stock Option (Right to Buy) | 2025-01-28 | M | D | 25,000 | $0.00 | 175,000 | D | $7.08 · — to 2033-08-17 | 25,000 Common Stock | (F4) 1/48th of the shares subject to the option vest each month beginning on September 17, 2023, subject to the Reporting Person continuing as a service provider through each vest date. |